Effect and mechanism of ginsenoside Rg1-regulating hepatic steatosis in HepG2 cells induced by free fatty acid

References

• Chalasani N, Younossi Z, Lavine JE, et al. diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases. Hepatology. 2018;67:328–357.
   PubMed Web of Science ®Google Scholar
• Eslam M, George J. Genetic insights for drug development in NAFLD. Trends Pharmacol Sci. 2019;40:506–516.
   PubMed Web of Science ®Google Scholar
• ZM Y, AB KDA, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73–84.
   PubMed Web of Science ®Google Scholar
• Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Clin Pract Gastroenterol Hepatol. 2017;15:11–20.
   Google Scholar
• Singh S, Osna NA, Kharbanda KK. Kharbanda KK.Treatment options for alcoholic and non-alcoholic fatty liver disease: A review. World J Gastroenterol. 2017;23:6549–6570.
   PubMed Web of Science ®Google Scholar
• Nguyen P, Leray V, Diez M, et al. Liver lipid metabolism. J Anim Physiol Anim Nutr (Berl). 2008;92:272–283.
   PubMed Web of Science ®Google Scholar
• Bechmann LP, Hannivoort RA, Gerken G, et al. interaction of hepatic lipid and glucose metabolism in liver diseases. J Hepatol. 2012;56:952–964.
   PubMed Web of Science ®Google Scholar
• Bessone F, Razori MV, Roma MG. Molecular pathways of nonalcoholic fatty liver disease development and progression. Cell Mol Life Sci. 2019;76:99–128.
   PubMed Web of Science ®Google Scholar
• Fang K, Wu F, Chen G, et al. ameliorates palmitic acid-induced lipid accumulation via AMPK/ACC/CPT-1A and SREBP-1c/FAS signaling pathways in LO2 cells. BMC Complement Altern Med. 2019;19:255.
   PubMed Web of Science ®Google Scholar
• Mashek DG. Hepatic fatty acid trafficking: multiple forks in the road. Adv Nutr. 2013;4(6):697–710.
   PubMed Web of Science ®Google Scholar
• Yoon S, Kim J, Lee H, et al. effects of herbal composition Gambigyeongsinhwan (4) on hepatic steatosis and inflammation in otsuka long-evans tokushima fatty rats and HepG2 cells. J Ethnopharmacol. 2017;195:204–213.
   PubMed Web of Science ®Google Scholar
• Sirwi A, MM H. Lipid transfer proteins in the assembly of apoB-containing lipoproteins. J Lipid Res. 2018;59:1094–1102.
   PubMed Web of Science ®Google Scholar
• Kim JH, Yi Y-S, Kim M-Y, et al. Role of ginsenosides, the main active components of Panax ginseng, in inflammatory responses and diseases. J Ginseng Res. 2017;41:435–443.
   PubMed Web of Science ®Google Scholar
• Qin Q, Lin N, Huang H, et al. Ginsenoside Rg1 ameliorates cardiac oxidative stress and inflammation in streptozotocin-induced diabetic rats. Diabetes Metab Syndr Obes. 2019;12:1091–1103.
   PubMed Web of Science ®Google Scholar
• QF X, XL FDFC, Chen DF. Pharmacokinetics and bioavailability of ginsenoside Rb1 and Rg1 from Panax notoginseng in rats. J Ethnopharmacol. 2003;84:187–192.
   PubMed Web of Science ®Google Scholar
• Liu H, Yang J, Du F, et al. Absorption and disposition of ginsenosides after oral administration of Panax notoginseng extract to rats. Drug Metab Dispos. 2009;37:2290–2298.
   PubMed Web of Science ®Google Scholar
• Chu S-F, Zhang J-T. New achievements in ginseng research and its future prospects. Chin J Integr Med. 2009;15:403–408.
   PubMed Web of Science ®Google Scholar
• Wei Y, Li P, Fan H, et al. Metabolism study of notoginsenoside R1, ginsenoside Rg1 and ginsenoside Rb1 of radix Panax notoginseng in zebrafish. Molecules. 2011;16:6621–6633.
   PubMed Web of Science ®Google Scholar
• Hasegawa H. Proof of the mysterious efficacy of ginseng: basic and clinical trials: metabolic activation of ginsenoside: deglycosylation by intestinal bacteria and esterification with fatty acid. J Pharmacol Sci. 2004;95:153–157.
   PubMed Web of Science ®Google Scholar
• Choi SY, Park JS, Shon CH, et al. Fermented Korean red ginseng extract enriched in Rd and Rg3 protects against non-alcoholic fatty liver disease through regulation of mTORC1. Nutrients. 2019;11.
   Web of Science ®Google Scholar
• Xu Y, Yang C, Zhang S, et al. Ginsenoside Rg1 protects against non-alcoholic fatty liver disease by ameliorating lipid peroxidation, endoplasmic reticulum stress, and inflammasome activation. Biol Pharm Bull. 2018;41:1638–1644.
   PubMed Web of Science ®Google Scholar
• Xiao Q, Zhang S, Yang C, et al. Ginsenoside Rg1 ameliorates palmitic acid-induced hepatic steatosis and inflammation in HepG2 Cells via the AMPK/NF-kappaB pathway. Int J Endocrinol. 2019;2019:7514802.
   PubMed Web of Science ®Google Scholar
• Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62:S47–64.
   PubMed Web of Science ®Google Scholar
• Kanuri G, Bergheim I. In vitro and in vivo models of non-alcoholic fatty liver disease (NAFLD). Int J Mol Sci. 2013;14:11963–11980.
   PubMed Web of Science ®Google Scholar
• Long JK, Dai W, Zheng YW, et al. miR-122 promotes hepatic lipogenesis via inhibiting the LKB1/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease. Mol Med. 2019;25:26.
   PubMed Web of Science ®Google Scholar
• Marafie SK, Al-Shawaf EM, Abubaker J. Palmitic acid-induced lipotoxicity promotes a novel interplay between Akt-mTOR, IRS-1, and FFAR1 signaling in pancreatic β-cells. Biol Res. 2019;52:44.
   PubMed Web of Science ®Google Scholar
• Yao H-R, Liu J, Plumeri D. Lipotoxicity in HepG2 cells triggered by free fatty acids. Am J Transl Res. 2011;3:284–291.
   PubMed Web of Science ®Google Scholar
• Silva AKS, Peixoto CA. Role of peroxisome proliferator-activated receptors in non-alcoholic fatty liver disease inflammation. Cell Mol Life Sci. 2018;75:2951–2961.
   PubMed Web of Science ®Google Scholar
• Skat-Rordam J, Hojland Ipsen D, Lykkesfeldt J, et al. A role of peroxisome proliferator-activated receptor gamma in non-alcoholic fatty liver disease. Basic Clin Pharmacol Toxicol. 2019;124:528–537.
   PubMed Web of Science ®Google Scholar
• Pettinelli P, Videla LA. Up-regulation of PPAR-gamma mRNA expression in the liver of obese patients: an additional reinforcing lipogenic mechanism to SREBP-1c induction. J Clin Endocrinol Metab. 2011;96:1424–1430.
   PubMed Web of Science ®Google Scholar
• Marechal L, Laviolette M, Rodrigue-Way A, et al. The CD36-PPARgamma pathway in metabolic disorders. Int J Mol Sci. 2018;19. DOI:10.3390/ijms19051529.
   Web of Science ®Google Scholar
• Blanchard PG, Turcotte V, Cote M, et al. proliferator-activated receptor gamma activation favours selective subcutaneous lipid deposition by coordinately regulating lipoprotein lipase modulators, fatty acid transporters and lipogenic enzymes. Acta Physiol (Oxf). 2016;217:227–239.
   PubMed Web of Science ®Google Scholar
• Shah P, Mudaliar S. Pioglitazone: side effect and safety profile. Expert Opin Drug Saf. 2010;9:347–354.
   PubMed Web of Science ®Google Scholar
• Esler WP, Bence KK. Metabolic Targets in Nonalcoholic Fatty Liver Disease. Cell Mol Gastroenterol Hepatol. 2019;8:247–267.
   PubMed Web of Science ®Google Scholar
• Ameen C, Edvardsson U, Ljungberg A, et al. Activation of peroxisome proliferator-activated receptor alpha increases the expression and activity of microsomal triglyceride transfer protein in the liver. J Biol Chem. 2005;280:1224–1229.
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhang H, Deng X, et al. Baicalin attenuates non-alcoholic steatohepatitis by suppressing key regulators of lipid metabolism, inflammation and fibrosis in mice. Life Sci. 2018;192:46–54.
   PubMed Web of Science ®Google Scholar
• Tailleux A, Wouters K, Staels B. Roles of PPARs in NAFLD: potential therapeutic targets. Biochim Biophys Acta. 2012;1821:809–818.
   PubMed Web of Science ®Google Scholar
• Peng XE, Wu YL, Lu QQ, et al. MTTPpolymorphisms and susceptibility to non-alcoholic fatty liver disease in a Han Chinese population. Liver Int. 2014;34:118–128.
   PubMed Web of Science ®Google Scholar
• Chen XF, Tian MX, Sun RQ, et al. SIRT5 inhibits peroxisomal ACOX1 to prevent oxidative damage and is downregulated in liver cancer. EMBO Rep. 2018;19. DOI:10.15252/embr.201745124.
   Web of Science ®Google Scholar
• Nakagawa Y, Satoh A, Tezuka H, et al. CREB3L3 controls fatty acid oxidation and ketogenesis in synergy with PPARalpha. Sci Rep. 2016;6:39182.
   PubMed Web of Science ®Google Scholar
• Wang J, He W, Tsai P-J, et al. Mutual interaction between endoplasmic reticulum and mitochondria in nonalcoholic fatty liver disease. Lipids Health Dis. 2020;19:72.
   PubMed Web of Science ®Google Scholar
• Bakker SJL, IJzerman RG, Teerlink T, et al. Cytosolic triglycerides and oxidative stress in central obesity: the missing link between excessive atherosclerosis, endothelial dysfunction, and beta-cell failure? Atherosclerosis. 2000;148:17–21.
   PubMed Web of Science ®Google Scholar
• Ipsen DH, Lykkesfeldt J, Tveden-Nyborg P. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. Cell Mol Life Sci. 2018;75:3313–3327.
   PubMed Web of Science ®Google Scholar
• Geisler CE, Renquist BJ. Hepatic lipid accumulation: cause and consequence of dysregulated glucoregulatory hormones. J Endocrinol. 2017;234:R1–R21.
   PubMed Web of Science ®Google Scholar
• Yu Y, Cai J, She Z, et al. Insights into the epidemiology, pathogenesis, and therapeutics of nonalcoholic fatty liver diseases. Adv Sci (Weinh). 2019;6:1801585.
   PubMedGoogle Scholar
• Shen J, Sun B, Yu C, et al. Choline and methionineregulate lipid metabolism via the AMPK signalingpathway in hepatocytes exposed to high concentrationsof nonesterified fatty acids. J Cell Biochem.2019. DOI: 10.1002/jcb.29494.
   Google Scholar
• Garcia D, Shaw RJ. AMPK: mechanisms of cellular energy sensing and restoration of metabolic balance. Mol Cell. 2017;66:789–800.
   PubMed Web of Science ®Google Scholar
• Park M, Yoo JH, Lee YS, et al. Lonicera caerulea extract attenuates non-alcoholic fatty liver disease in free fatty acid-induced HepG2 hepatocytes and in high fat diet-fed mice. Nutrients. 2019;11. DOI:10.3390/nu11030494.
   Web of Science ®Google Scholar